Furthermore, in agreement with previous data (Wang et al, 2003; Voboril et al, 2004), inhibition of NF-κB also augmented sensitivity of HT-29 tumour cells to 5-FU, the most common antimetabolite used for the treatment of CRC and other types of solid tumours. Here, NFKB1 is linked to neoplasm.